-$0.18 EPS Expected for OncoSec Medical Inc (ONCS) This Quarter

Equities analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to report earnings of ($0.18) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings of ($0.28) per share during the same quarter last year, which indicates a positive year over year growth rate of 35.7%. The firm is scheduled to report its next quarterly earnings results on Wednesday, October 24th.

According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.93) per share for the current fiscal year, with EPS estimates ranging from ($0.95) to ($0.90). For the next year, analysts expect that the firm will post earnings of ($0.70) per share, with EPS estimates ranging from ($0.81) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for OncoSec Medical.

OncoSec Medical (NASDAQ:ONCS) last released its quarterly earnings data on Wednesday, June 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.04).

ONCS has been the subject of several analyst reports. HC Wainwright set a $4.00 price objective on shares of OncoSec Medical and gave the company a “buy” rating in a research note on Tuesday, August 7th. Dawson James reaffirmed a “buy” rating on shares of OncoSec Medical in a research note on Monday, July 16th. Finally, Piper Jaffray Companies lifted their price objective on shares of OncoSec Medical to $5.00 and gave the company an “overweight” rating in a research note on Tuesday, August 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $4.67.

In related news, CFO Richard B. Slansky sold 84,984 shares of OncoSec Medical stock in a transaction on Thursday, July 5th. The shares were sold at an average price of $1.39, for a total value of $118,127.76. Following the transaction, the chief financial officer now owns 255,000 shares in the company, valued at approximately $354,450. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Punit Dhillon sold 28,145 shares of OncoSec Medical stock in a transaction on Monday, June 18th. The stock was sold at an average price of $1.39, for a total transaction of $39,121.55. Following the completion of the transaction, the director now owns 355,702 shares in the company, valued at approximately $494,425.78. The disclosure for this sale can be found here. Insiders sold a total of 300,106 shares of company stock worth $419,658 in the last quarter. Insiders own 5.50% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Millennium Management LLC increased its holdings in shares of OncoSec Medical by 19.5% during the 2nd quarter. Millennium Management LLC now owns 1,195,315 shares of the biotechnology company’s stock worth $1,650,000 after purchasing an additional 194,739 shares during the period. Nexthera Capital LP increased its holdings in shares of OncoSec Medical by 26.6% during the 2nd quarter. Nexthera Capital LP now owns 2,614,297 shares of the biotechnology company’s stock worth $3,608,000 after purchasing an additional 550,000 shares during the period. DRW Securities LLC increased its holdings in shares of OncoSec Medical by 157.1% during the 2nd quarter. DRW Securities LLC now owns 180,000 shares of the biotechnology company’s stock worth $248,000 after purchasing an additional 110,000 shares during the period. BlackRock Inc. increased its holdings in shares of OncoSec Medical by 1,303.5% during the 2nd quarter. BlackRock Inc. now owns 238,940 shares of the biotechnology company’s stock worth $330,000 after purchasing an additional 221,916 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of OncoSec Medical by 47.5% during the 1st quarter. Point72 Asset Management L.P. now owns 3,215,000 shares of the biotechnology company’s stock worth $6,044,000 after purchasing an additional 1,035,000 shares during the period. Hedge funds and other institutional investors own 26.16% of the company’s stock.

Shares of ONCS stock traded down $0.06 on Wednesday, hitting $1.41. The company’s stock had a trading volume of 534,160 shares, compared to its average volume of 597,358. OncoSec Medical has a fifty-two week low of $0.90 and a fifty-two week high of $2.95. The firm has a market cap of $76.95 million, a PE ratio of -1.33 and a beta of 2.90.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Further Reading: Are Wall Street analysts’ stock ratings worth following?

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply